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Abstract The possible role of sphingomyelin cycle for the regu- 
lation of cell proliferation was investigated in human ker- 
atinocytes. The time-dependent breakdown of sphingomyelin was 
observed in the immortalized human keratinocyte cell line 
HaCaT as well as in primary human keratinocytes thereby pro- 
viding evidence that the sphingomyelin cycle might be of impor- 
tance in the epidermis. Peak levels of 20-30% sphingomyelin 
hydrolysis were measured 3 h after treatment of the cells with 
lcu,25-dihydroxyvitamin D3 or with the vitamin D, analogue, 
calcipotriol. The decrease of sphingomyelin upon addition of vita- 
min D3 or calcipotriol was accompanied by an approximately 
70% increase of ceramide in the cells. The effects of vitamin D, 
and calcipotriol on sphingomyelin breakdown were paralleled by 
their antiproliferative potency. Furthermore, the cell-permeable 
ceramide, N-acetylsphingosine, and natural ceramide inhibited 
cell proliferation of human keratinocytes. The results presented 
suggest that induction of the sphingomyelin cycle represents one 
mechanism mediating the therapeutic effect of calcipotriol in 
treatment of psoriasis. 
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1. Introduction 
The sphingomyelin (SM) cycle has been initially identified in 
HL-60 human leukemia cells as a new cellular signalling path- 
way in response to vitamin D, [l]. It has been shown that a 
time-dependent and reversible hydrolysis of SM occurs via ac- 
tivation of a sphingomyelinase generating ceramide [2]. Subse- 
quently, the SM cycle is completed by the transfer of a choline 
head group from phosphatidylcholine to ceramide [3]. Up to 
now, several other agonists of the SM cycle have been de- 
scribed, including tumor necrosis factor c1 (TNFa), y-inter- 
feron, dexamethasone. interleukin-I, nerve growth factor 
(NGF), complement and brefeldin A (for review. see [4,5]). It 
has been implicated that the SM cycle mediates the effects 
of these agonists finally leading to terminal differentiation or 
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apoptosis [6,7]. Using cell-permeable ceramide analogues, it was 
possible to mimick the effects of several inducers of SM hydrol- 
ysis on cell proliferation and differentiation [8]. 
Psoriasis is a disease of the skin which is characterized by an 
enormous hyperproliferation of keratinocytes and the topical 
treatment with antiproliferative agents represents a classical 
concept of therapy [9]. Calcipotriol (MC 903) is a vitamin D, 
analogue which has been found to potently induce cell differen- 
tiation and inhibit cell proliferation cells possessing the receptor 
for Isr,25-dihydroxyvitamin D, by an unknown mechanism 
[ 10,l 11. Furthermore, topical treatment of psoriasis with calci- 
potriol has been shown to constitute an effective and potent 
therapy for this skin disease [12]. Therefore, the elucidation of 
the mechanism underlying the therapeutic effect of calcipotriol 
is of great interest and might lead to the development of new 
drugs. 
In the present study, the existence of a lcr,25-dihydroxy- 
vitamin D, inducible SM cycle was demonstrated in human ker- 
atinocytes. Additionally, the vitamin D, analogue, calcipotriol, 
was found to induce the hydrolysis of 20-30% of total cellular 
SM and to increase the formation of ceramide in a time-de- 
pendent and reversible manner, with maximal activity after 
3 h. la,25-dihydroxyvitamin D, as well as calcipotriol inhibited 
the proliferation of keratinocytes and HaCaT cells and their 
antiproliferative effects were mimicked by N-acetylsphingosine 
(C,-ceramide) and natural ceramide. Hence, the SM cycle is 
discussed as a possible mechanism underlying the antiprolifera- 
tive effect of calcipotriol in psoriasis. 
2. Materials and methods 
2.1. Mtrteriuls 
Streptomyces sp. sphingomyelase, dodecane and ceramide (from bo- 
vine brain SM or cerebroside) were purchased from Sigma (Miinchen, 
Germany). Solvents and reagents (reagent grade) were obtained from 
Merck (Darmstadt, Germany) and Fluka (Neu-Ulm, Germany). Triton 
X-100 was purchased from Aldrich (Steinheim, Germany). [methpl- 
‘HICholine chloride (2.8-3.1 TBq/mmol), [IV-mrthy[-‘“C]SM (2.07 
GBq/mmol), L-3-phosphatidyl-[N-methy/-3H]choline, 1,2-dipalmitoyl 
(2.44 TBq/mmol) and L-[3-‘Hlserine (1.11 TBq/mmol) were from Amer- 
sham (Braunschweig, Germany). N-Acetylsphingosine (Cz-ceramide) 
was from Alexis (Griinberg, Germany). la,25-dihydroxyvitamin D, 
and calcipotriol (MC 903) were a gift from Dr. L. Binderup (Leo 
Pharmaceutical Products; Kopenhagen, Denmark). For quantification 
of radioactivity a Berthold (Wildbad, Germany) LB 2821 HR thin-layer 
chromatography scanner was used. 
2.2. C&l culture 
HaCaT cells [13] were grown in RPM1 medium supplemented with 
10% heat-inactivated fetal calf serum, 0.35 g/l glutamine, 100 000 lull 
penicillin and 0.1 g/l streptomycin in plastic culture dishes (Nunc; 
Wiesbaden, Germany). Media and culture reagents were obtained from 
Gibco (Karlsruhe, Germany). Penicillin and streptomycin were from 
Boehringer (Mannheim, Germany). Human keratinocytes were pre- 
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pared from human forskin as described recently [14] and cultured in 
keratinocyte growth medium (KGM). KGM was prepared from ker- 
atinocyte basal medium (KBM) by addition of 10 ng/ml epidermal 
growth factor, 5 pug/ml insulin, 0.5 PM hydrocortisone, 50 &ml bovine 
pituitary extract, lOOyg/ml penicillin/streptomycin, and 2.5 /@ml fun- 
gizone. KBM consisted of MCDB 153 medium as described [15] which 
was supplemented with 100 yM ethanolamine, 100 yM phosphoetha- 
nolamine, 240 PM histidine, 750 PM isoleucine, 90 PM methionine, 90 
PM phenylalanine, 45 PM tryptophan, 75 PM tyrosine and 150 PM 
CaCI,. KBM and supplements were purchased from Clonetics (San 
Diego, CA, USA). la,25_dihydroxyvitamin D, and calcipotriol were 
diluted into KBM or KGM as described above from 10 PM stock 
ethanol solutions. Ceramide was first dissolved in ethanol/dodecane 
(98:2, v/v) at a concentration of 177 PM as described [16]. 
The solution was then added to KGM and sonicated for 30 min. 
Cz-ceramide was diluted into KGM from a 30 mM stock dimethyl 
sulphoxide solution. Ethanol, ethanol/dodecane (98 : 2, v/v) and di- 
methyl sulphoxide (vehicles) were added to controls and were present 
at l%, 0.56% and O.l%, respectively. 0.1% dimethyl sulphoxide did not 
significantly reduce the proliferation rate of human keratinocytes (98% 
of controls). The same was true for 1% ethanol and 0.56% ethanol/ 
dodecane (98 : 2, v/v). 
was quantified by radioscanning. SM and phosphatidylcholine were 
identified by calibrating the scanner with know standards. A compari- 
son of the thin-layer chromatography method with the sphingomyeli- 
nase method demonstrated that the methods gave identical results (23% 
SM-hydrolysis as compared with control after 60 min of stimulation 
with TNFa). 
2.5. Determination of cellular crrumide 
2.3. Choline labelling of cells 
For choline labelling of HaCaT cells and human keratinocytes, me- 
dium was removed and pulse medium (KGM containing 3.7 x lo4 Bql 
ml [methy/-iH]chohne) was added. After incubation for 72 h, cells were 
washed twice with phosphate-buffered saline (PBS) and then treated 
with 100 nM la,25-dihydroxyvitamin D, or 100 nM calcipotriol in 
KBM for different time periods. Cells were harvested in 400~1 ice-cold 
PBS by use of a cell lifter (Costar; Cambridge, MA, USA). After 
freeze-drying of the cells, lipids were extracted by a modified method 
of Bligh and Dyer [17] as described [18]. Total lipid extracts were dried 
under a stream of nitrogen and stored at -20°C. 
The formation of cellular ceramide upon addition of la,25-dihy- 
droxyvitamin D, or calcipotriol was determined as described [21]. 
Briefly, subconfluent cells were radiolabelled by the addition of 
L-[‘Hlserine (2 ,@.Zi/ml) to serine-free Minimal Essential Medium (Gibco; 
Karlsruhe, Germany) containing 5% heat-inactivated fetal calf serum 
for 24 h. The confluent cells were washed twice with PBS and incubated 
for 5 h in KGM containing unlabelled serine (5 mM). The cells were 
washed as before and then treated with 100 nM la,25-dihydroxy- 
vitamin D, or 100 nM calcipotriol in KBM for different time periods. The 
medium was removed, and the cells were precipitated in 0.5 ml metha- 
nol. Lipids were extracted by addition of 0.25 ml chloroform and 
incubation for 1 h followed by addition of 0.75 ml chloroform and 
incubation for a further 30 min. The phases were separated by the 
addition of 0.75 ml water and the organic phase was removed and dried 
under a stream of nitrogen. Lipids were solubilized in chloroform/ 
methanol (2: 1, v/v), separated by high-performance thin-layer chroma- 
tography using the solvent system chloroform/methanol (9 : 1, v/v), and 
radioactivity was quantified by radioscanning. Ceramide was identified 
by calibrating the scanner with radiolabelled ceramide which was pre- 
pared by incubation of serine-labelled cells with 0.1 unit/ml sphingomy- 
ehnase. The ceramide-bound radioactivity of control samples at time 
point 0 was 0.66% of total radioactivity. Total radioactivity in the 
samples normally reached 50,000 cpm. The ceramide-bound radioactiv- 
ity of control samples was set as 100% and ceramide in the samples of 
la,25-dihydroxyvitamin D, or calcipotriol-treated cells was calculated 
as % of control. 
2.4. Sphingomyelin yuantitation 2.6. Ceil prolijeration assays 
SM was quantified using bacterial sphingomyelinase to release 
[‘Hlphosphocholine as described recently [19]. Briefly, the total lipid 
extracts were resuspended in 100 ~1 of assay buffer (100 mM Tris-HCI, 
pH 7.4, 6 mM MgC&, 0.1% Triton X-100). The samples were sonicated 
for 5 min and I unit/ml sphingomyelinase from Streptomyces sp. was 
added. After incubation at 37°C for 2 h, the reaction was stopped by 
addition of 1 ml chloroform/methanol (2: 1, v/v) and the liberated 
[‘Hlphosphocholine was recovered with the aqueous phase of a Folch 
extraction [20]. Phase separation was completed by addition of 100 ~1 
water and the aqueous phase was taken for scintillation counting. The 
radioactivity of the aqueous phase normally reached 10,000 cpm and 
the radioactivity in control samples was set as 100%. Subsequently, SM 
in the samples of calcipotriol or la,25_dihydroxyvitamin D,-treated 
cells was calculated as % of control. The assay conditions described 
above were verified using [methyl-‘+‘C]SM and [methyl-‘Hlphosphati- 
dylcholine. As shown in Table 1, maximal SM hydrolysis (> 98%) 
without accompanying phosphatidylcholine hydrolysis (c 5%) was ob- 
served. 
Human keratinocytes and HaCaT cells were seeded in 96-multiwell 
plastic culture dishes with a density of 5 x 10’ cells/cm’ and treated with 
different concentrations of la,25_dihydroxyvitamin D,, calcipotriol. 
natural ceramide or C,-ceramide in KGM. After incubation for 2472 
h, the cells were washed twice with PBS and cell proliferation was 
determined by the MUH fluorescence assay using 4-methylumbelliferyl 
heptanoate (Serva, Heidelberg, Germany) as described recently [22]. 
The absolute fluorescence units of control cells were set as 100% and 
the proliferation rate of treated cells was calculated as % of control. 
Additionally, cell proliferation was determined by the crystal violet 
assay as described in detail [23]. Both assays gave similar results. 
2.7. Other procedures 
Statistical comparisons were made in these studies with Student’s 
t-test. 
3. Results and discussion 
Furthermore, SM was also determined by a thin-layer chromatogra- 
phy method. Lipids were spotted on silica gel 60 high-performance 
thin-layer chromatography plates and plates were developed in chloro- 
form/methanol/triethyI-amine/water (30: 35 : 34: 8, by vol). Radioactivity 
3.1. Calcipotriol time-dependently activates sphingonzyelin 
hydrolysis 
In keratinocytes, the existence of the SM cycle has not been 
Table 1 
Distribution of radioactivity between the aqueous and organic phases after sphingomyelinase treatment 
Sample Radioactivity in the aqueous phase (% of total cpm) 
[methyl-‘4C]SM + enzyme 98.4 
[methyl-‘+‘C]SM - enzyme 0.7 
[methyl-‘Hlphosphatidyl- 
Radioactivity in the organic phase (% of total cpm) 
1.6 
99.3 
choline + enzyme 4.2 95.8 
[methy/-‘H]phosphatidyl- 
choline - enzyme 1.3 98.7 
Trace-amounts of [methyl-‘“C]SM (44,000 dpm) or [methyl-‘Hlphosphatidylcholine (440,000 dpm) were added to a total lipid extract from HaCaT 
cells. Then, sphingomyelinase assays were performed as described in section 2 and 400 ~1 of the aqueous phases and 800 ~1 of the organic phases 
were taken for scintillation counting. Values are given as % of total radioactivity and represent the mean of two determinations with an error less 
than 1%. The experiment was repeated with purified SM and purified phosphatidylchohne and similar results were obtained. 
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demonstrated yet. We therefore tested the known inducer of 
SM hydrolysis, la,25_dihydroxyvitamin D,, in human ker- 
atinocytes and in the immortalized human keratinocyte cell line 
HaCaT. As expected, a time-dependent effect of lc1.25-dihy- 
droxyvitamin D, on SM hydrolysis occurred in HaCaT cells 
(Fig. 1A). The hydrolysis of approximately 25% of total cellular 
SM was observed after 3 h of la,25-dihydroxyvitamin D, treat- 
ment and SM levels returned to control levels by 6 h. Similar 
results were obtained in primary keratinocytes (data not 
shown). The amount of hydrolyzed SM and the time course of 
SM hydrolysis are in accordance with results obtained in the 
leukemic cell line HL-60 [l]. TNFa, another well known in- 
ducer of the SM cycle [19,24], also activated SM hydrolysis in 
kerdtinocytes and HaCaT cells (data not shown). Thus, our 
results provide strong experimental evidence that the agonist- 
stimulated hydrolysis of SM represents an operative signal 
transduction pathway in keratinocytes. This might be of future 
interest since both SM and sphingomyelinase are present in the 
epidermis [25,26] and the importance of ceramides in the skin 
barrier system has been discussed [27]. 
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In another set of experiments, we investigated the effects of 
the vitamin D, analogue, calcipotriol, on SM hydrolysis. As 
shown in Fig. IB, incubation of HaCaT cells with 100 nM 
calcipotriol led to the time-dependent hydrolysis of SM. Maxi- 
mal effects of approximately 30% SM hydrolysis were observed 
3 h after treatment with calcipotriol and the time course of the 
calcipotriol effect resembled the vitamin D, effect described in 
the previous paragraph. Furthermore, nearly the same effects 
of calcipotriol were observed in primary kerdtinocytes (data not 
shown). The known activators of the SM cycle may be catego- 
rized by the temporal nature of their activation. Early activa- 
tors, such as TNFcl and interleukin-1, cause SM hydrolysis 
within 15-30 min whereas late activators, such as vitamin D? 
and y-interferon, show stimulation of SM hydrolysis after 2 h 
Fig. 2. Time-dependent formation of ceramide after Ia,25-dihydroxy- 
vitamin D, or calcipotriol treatment of HaCaT cells. Subconfluent 
HaCaT cells were labelled for 24 h with serine-free medium containing 
7.4 x 10” Bq/ml t-[‘Hlserine. Pulse medium was removed and the cells 
were incubated for 5 h with KGM containing 5 mM unlabelled serine. 
Then, the cells were treated with 100 nM la,25_dihydroxyvitamin D, 
(A) or calcipotriol (B). Control media contained 1% ethanol. After 
different incubation times as indicated in the figure, the cells were 
harvested and cellular ceramide was quantitated as described in section 
2. Values represent the mean of three experiments and the standard 
deviation is shown as a vertical bar. *Significantly different from con- 
trols at P c 0.02. **Significantly different from controls at P < 0.01. 
of treatment [3]. From the results obtained we suggest that 
calcipotriol is a late inducer of the SM cycle. 
3.2. Culcipotriol time-dependently induces formation of 
ceramide 
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Fig. 1. Time-dependent hydrolysis of sphingomyelin after I a,25-dihy- 
droxyvitamin D, or calcipotriol treatment of HaCaT cells. Subconflu- 
ent HaCaT cells were labelled for 72 h with pulse medium containing 
3.7 x IO” Bq/ml [nzrth?,l-3H]choline. Pulse medium was removed and the 
cells were treated with 100 nM Ia,25-dihydroxyvitamin D, (A) or cal- 
cipotriol (B). Control media contained 1% ethanol. After different 
incubation times as indicated in the figure, the cells were harvested and 
SM was quantitated as described in section 2. Values represent the 
mean of three experiments and the standard deviation is shown as a 
vertical bar. *Significantly different from controls at P < 0.05. **Signif- 
icantly different from controls at P < 0.02. 
It has been shown that treatment of HL-60 cells with vitamin 
D, resulted in an increase of cellular ceramide with peak levels 
after 2 h [l]. To demonstrate that vitamin D, as well as calci- 
potriol not only activated SM hydrolysis but at the same time 
induced the formation of cellular ceramide we metabolically 
labelled the lipid backbone of SM by addition of L-[3H]serine 
to the medium of the cells. When keratinocytes (data not 
shown) or HaCaT cells were treated with either vitamin D, 
(Fig. 2A) or calcipotriol (Fig. 2B) an approximately 70% in- 
crease of cellular ceramide was observed after 3 h and ceramide 
returned to base-line levels by 446 h. The time-dependent for- 
mation of ceramide is in accordance with the time-course of SM 
hydrolysis thereby confirming the metabolic pathway involved 
in SM hydrolysis which has been characterized in HL-60 cells 
VI. 
3.3. Antiproliferative effects of calcipotriol, 
la,2Sdihydroxyvitamin D,, natural ceramide and 
C,-ceramide on human keratinocytes and HaCaT cells 
To investigate the antiproliferative effect of calcipotriol in 
comparison with the effect of la,25-dihydroxyvitamin D,, ker- 
atinocytes and HaCaT cells were incubated with different 
amounts of both substances and the concentration-dependent 
effects on cell proliferation were measured. As shown in Fig. 
3A, keratinocytes were more sensitive to incubation with low 
concentrations (c G 100 nM) of calcipotriol or lol,25-dihy- 
droxyvitamin D, as compared with HaCaT cells and cell prolif- 
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Fig. 3. Antiproliferative effects of la,25-dihydroxyvitamin D, and cal- 
cipotriol on human keratinocytes and HaCaT cells. 5 x 10’ ker- 
atinocytes/cm* (A) and 5 x IO3 HaCaT cells/cm’ (B) were treated with 
different concentrations of Ia,25-dihydroxyvitamin D, (0) or calcipot- 
rioI( Control media contained 1% ethanol. After 48 h (HaCaT cells) 
and 72 h (keratinocytes), cell proliferation was determined by the MUH 
fluorescence assay as described in section 2. Values represent the mean 
of four experiments and the standard deviation is shown as a vertical 
bar. *Significantly different from controls at P < 0.02. **Significantly 
different from controls at P < 0.01. ***Significantly different from con- 
trols at P < 0.001. 
eration was inhibited by about 40% in the presence of 100 nM 
calcipotriol or I d,25-dihydroxyvitamin D,. However, signifi- 
cant antiproliferative effects of both compounds were also ob- 
served in HaCaT cells at higher concentrations (Fig. 3B). 
There have been a lot of implications in the literature that 
the SM cycle plays an important role in the negative regulation 
of cell proliferation and it has been shown that inducers of SM 
hydrolysis, such as vitamin D, and TNFa, caused growth inhi- 
bition of HL-60 cells [28] and human keratinocytes [29]. Fur- 
thermore, 4 days after addition of sphingomyelinase to the 
culture medium of HL-60 cells a decrease in cell proliferation 
was observed [l] suggesting that SM breakdown and increased 
levels of ceramides are responsible for the antiproliferative ef- 
fect. Hence, we used the cell-permeable ceramide, acetylsphin- 
gosine (C,-cerdmide), and natural ceramide in our experimental 
system. C$ceramide inhibited cell proliferation of ker- 
atinocytes (data not shown) and HaCaT cells (Fig. 4) in the low 
pmolar range thereby confirming the results from another lab- 
oratory [30]. By using conditions which allowed ceramide pen- 
etration into cells [16] we could demonstrate that natural cer- 
amide derived from sphingomyelin (ceramide III) or cerebrosid 
(ceramide IV) inhibited proliferation of HaCaT cells by 21% 
and 40%, respectively (Fig. 4). 
In conclusion, we provide evidence that the SM cycle. a 
signalling pathway originally described in HL-60 cells, is also 
found in the immortalized human keratinocyte cell line HaCaT 
and in human keratinocytes. In addition to the known inducers 
of SM hydrolysis, 1 a,25_dihydroxyvitamin D, and TNFa, both 
cell types responded to the antiproliferative, synthetic vitamin 
D, analogue, calcipotriol. Acetylsphingosine, a cell-permeable, 
short chain ceramide which is similar to the naturally occurring 
breakdown product of SM hydrolysis, mimicked the effects of 
calcipotriol and lol,25-dihydroxyvitamin D? on cell prolifera- 
tion. Therefore, we suggest that the induction of the SM cycle 
is one possible mechanism underlying the antiproliferative 
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Fig. 4. Antiproliferative effects of Cz-ceramide and natural ceramide on 
HaCaT cells. 5 x 10’ HaCaT cells/cm’ were treated with different con- 
centrations of Cz-ceramide or with different concentrations of natural 
ceramide. Control media contained 0.1% dimethyl sulphoxide or 0.56% 
ethanolldodecane (98 : 2, v/v). After 24 h. cell proliferation was deter- 
mined as described in section 2. Values represent the mean of four 
experiments and the standard deviation is shown as a vertical bar. 
*Significantly different from controls at P < 0.05. **Significantly dif- 
ferent from controls at P < 0.01. ***Significantly different from con- 
trols at P < 0.001. 
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effect of the non-calcemic vitamin D, analogue, calcipotriol, 
which is used in the topical treatment of psoriasis. 
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